RTX, which medically stands for rituximab, is a common clinical antitumor drug, commonly used in injectable form, such as rituximab injection, mostly for intravenous infusion. The main active ingredient of rituximab is recombinant rituximab, which is mostly used for the treatment of relapsed or drug-resistant follicular central lymphoma, and can be used in combination with chemotherapy for patients with previously untreated CD20-positive stage III-IV follicular non-Hodgkin’s lymphoma. Care should be taken during administration to strictly follow the dosage and rate of administration as prescribed by the doctor, closely observe the patient’s vital signs with the drug, and avoid co-administration with other drugs to avoid adverse drug reactions.